The other issue here is that Amphastar (and Teva for that matter) did not know about the MNTA patents when they were developing their process. So although I have said that typically one can circumvent process-type patents, that assumes you know about them from the outset, which is not the case here.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.